<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="102662"><DrugName>sodium benzoate (urea cycle disorders), Lucane Pharma</DrugName><DrugNamesKey><Name id="43097764">Prohippur</Name><Name id="43124166">Prohippur, Lucane Pharma</Name><Name id="156051">sodium benzoate</Name></DrugNamesKey><DrugSynonyms><Name><Value>sodium benzoate</Value><Types><Type>USAN</Type></Types></Name><Name><Value>sodium benzoate (urea cycle disorders), Lucane Pharma</Value></Name><Name><Value>Prohippur</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Prohippur, Lucane Pharma</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>532-32-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1066794">Lucane Pharma SA</CompanyOriginator><CompaniesPrimary><Company id="1066794">Lucane Pharma SA</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1066794" type="Company"><TargetEntity id="5037133800" type="organizationId">Lucane Pharma SA</TargetEntity></SourceEntity><SourceEntity id="1820" type="ciIndication"><TargetEntity id="10052450" type="MEDDRA"></TargetEntity><TargetEntity id="D020163" type="MeSH"></TargetEntity><TargetEntity id="664" type="ORPHANET"></TargetEntity><TargetEntity id="-1633074271" type="omicsDisease"></TargetEntity><TargetEntity id="4511" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2284" type="ciIndication"><TargetEntity id="10001939" type="MEDDRA"></TargetEntity><TargetEntity id="D000608" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="2306" type="ciIndication"><TargetEntity id="E72.23" type="ICD10"></TargetEntity><TargetEntity id="D020159" type="MeSH"></TargetEntity><TargetEntity id="187" type="ORPHANET"></TargetEntity><TargetEntity id="-1978610149" type="omicsDisease"></TargetEntity><TargetEntity id="1653" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3144" type="ciIndication"><TargetEntity id="10020575" type="MEDDRA"></TargetEntity><TargetEntity id="D022124" type="MeSH"></TargetEntity><TargetEntity id="-395037315" type="omicsDisease"></TargetEntity><TargetEntity id="2240" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3852" type="ciIndication"><TargetEntity id="D020165" type="MeSH"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1820">Ornithine transcarbamylase deficiency</Indication><Indication id="2284">Aminoaciduria</Indication><Indication id="2306">Citrullinuria</Indication><Indication id="3143">N-acetylglutamate synthase deficiency</Indication><Indication id="3144">Hyperammonemia</Indication><Indication id="3852">Carbamoyl phosphate synthase I deficiency</Indication></IndicationsPrimary><Technologies><Technology id="603">Systemic formulation unspecified</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2018-06-25T13:17:10.000Z</LastModificationDate><ChangeDateLast>2018-05-02T00:00:00.000Z</ChangeDateLast><AddedDate>2016-07-01T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1066794" linkType="Company"&gt;Lucane Pharma&lt;/ulink&gt; is developing sodium benzoate for the potential treatment of urea cycle disorders including carbamoyl-phosphate synthetase-1 deficiency, citrullinemia type 1, hyperargininemia, ornithine transcarbamylase deficiency, ornithine translocase deficiency, lysinuric protein intolerance, argininosuccinic aciduria and N-acetylglutamate synthase deficiency [&lt;ulink linkID="1775672" linkType="Reference"&gt;1775672&lt;/ulink&gt;]. By March 2017, an  MAA had been submitted in the EU [&lt;ulink linkID="1913059" linkType="Reference"&gt;1913059&lt;/ulink&gt;]; however, in April 2018, Lucane Pharma withdrew its application; at that time, the company was defining a strategy to re-submit the application [&lt;ulink linkID="2028694" linkType="Reference"&gt;2028694&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;By March 2017, Lucane had filed an MAA for sodium benzoate in the EU [&lt;ulink linkID="1913059" linkType="Reference"&gt;1913059&lt;/ulink&gt;]. However, in April 2018, Lucane Pharma withdrew its application for the treatment of non-ketonic hyperglycinaemia and urea cycle disorders. The withdrawal was based on the CHMP opinion considering that the provided data did not allow concluding on a positive benefit risk balance. At that time, the company was defining a strategy to re-submit the application [&lt;ulink linkID="2028694" linkType="Reference"&gt;2028694&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, the EMA's COMP recommended granting sodium benzoate Orphan designations for the treatment of carbamoyl-phosphate synthetase-1 deficiency, citrullinemia type 1, hyperargininemia, and transcarbamylase deficiency [&lt;ulink linkID="1775672" linkType="Reference"&gt;1775672&lt;/ulink&gt;]; in July 2016, Orphan designations for these four indications were granted [&lt;ulink linkID="1782604" linkType="Reference"&gt;1782604&lt;/ulink&gt;]. In July 2016, the COMP recommended granting Orphan designations to sodium benzoate for the treatment of ornithine translocase deficiency and lysinuric protein intolerance [&lt;ulink linkID="1782604" linkType="Reference"&gt;1782604&lt;/ulink&gt;]; in August 2016, both Orphan designations were granted [&lt;ulink linkID="1798089" linkType="Reference"&gt;1798089&lt;/ulink&gt;]. In October 2016, the COMP recommended sodium benzoate for Orphan designation for the treatment of argininosuccinic aciduria and N-acetylglutamate synthase deficiency [&lt;ulink linkID="1834520" linkType="Reference"&gt;1834520&lt;/ulink&gt;]; in November 2016, Orphan drug designations for these indications were granted [&lt;ulink linkID="1887616" linkType="Reference"&gt;1887616&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1066794">Lucane Pharma SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3852">Carbamoyl phosphate synthase I deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-14T00:00:00.000Z</StatusDate><Source id="1775672" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1066794">Lucane Pharma SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2284">Aminoaciduria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-11T00:00:00.000Z</StatusDate><Source id="1782604" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1066794">Lucane Pharma SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3143">N-acetylglutamate synthase deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-10-04T00:00:00.000Z</StatusDate><Source id="1834520" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1066794">Lucane Pharma SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2306">Citrullinuria</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-14T00:00:00.000Z</StatusDate><Source id="1775672" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1066794">Lucane Pharma SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3144">Hyperammonemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-11T00:00:00.000Z</StatusDate><Source id="1782604" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1066794">Lucane Pharma SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1820">Ornithine transcarbamylase deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-14T00:00:00.000Z</StatusDate><Source id="1775672" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1066794">Lucane Pharma SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3144">Hyperammonemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-03-15T00:00:00.000Z</StatusDate><Source id="1913059" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1066794">Lucane Pharma SA</OwnerCompany><Country id="EU">EU</Country><Indication id="3144">Hyperammonemia</Indication><AwardedIndication>treatment of N-acetylglutamate synthase deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-11-18T00:00:00.000Z</MileStoneDate><Source id="1887616" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1066794">Lucane Pharma SA</OwnerCompany><Country id="EU">EU</Country><Indication id="2284">Aminoaciduria</Indication><AwardedIndication>treatment of argininosuccinic aciduria</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-11-18T00:00:00.000Z</MileStoneDate><Source id="1887616" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1066794">Lucane Pharma SA</OwnerCompany><Country id="EU">EU</Country><Indication id="3144">Hyperammonemia</Indication><AwardedIndication>treatment of N-acetylglutamate synthase deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-10-06T00:00:00.000Z</MileStoneDate><Source id="1834520" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1066794">Lucane Pharma SA</OwnerCompany><Country id="EU">EU</Country><Indication id="2284">Aminoaciduria</Indication><AwardedIndication>treatment of argininosuccinic aciduria</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-10-06T00:00:00.000Z</MileStoneDate><Source id="1834520" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1066794">Lucane Pharma SA</OwnerCompany><Country id="EU">EU</Country><Indication id="3144">Hyperammonemia</Indication><AwardedIndication>Treatment of lysinuric protein intolerance</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-29T00:00:00.000Z</MileStoneDate><Source id="1798089" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1066794">Lucane Pharma SA</OwnerCompany><Country id="EU">EU</Country><Indication id="3144">Hyperammonemia</Indication><AwardedIndication>Treatment of ornithine translocase deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-29T00:00:00.000Z</MileStoneDate><Source id="1798089" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1066794">Lucane Pharma SA</OwnerCompany><Country id="EU">EU</Country><Indication id="1820">Ornithine transcarbamylase deficiency</Indication><AwardedIndication>Treatment of ornithine transcarbamylase deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-14T00:00:00.000Z</MileStoneDate><Source id="1782604" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1066794">Lucane Pharma SA</OwnerCompany><Country id="EU">EU</Country><Indication id="2284">Aminoaciduria</Indication><AwardedIndication>Treatment of hyperargininaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-14T00:00:00.000Z</MileStoneDate><Source id="1782604" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1066794">Lucane Pharma SA</OwnerCompany><Country id="EU">EU</Country><Indication id="2306">Citrullinuria</Indication><AwardedIndication>Treatment of citrullinaemia type 1</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-14T00:00:00.000Z</MileStoneDate><Source id="1782604" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1066794">Lucane Pharma SA</OwnerCompany><Country id="EU">EU</Country><Indication id="3852">Carbamoyl phosphate synthase I deficiency</Indication><AwardedIndication>Treatment of carbamoyl-phosphate synthase-1 deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-14T00:00:00.000Z</MileStoneDate><Source id="1782604" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1066794">Lucane Pharma SA</OwnerCompany><Country id="EU">EU</Country><Indication id="3144">Hyperammonemia</Indication><AwardedIndication>Treatment of lysinuric protein intolerance</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-13T00:00:00.000Z</MileStoneDate><Source id="1782604" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1066794">Lucane Pharma SA</OwnerCompany><Country id="EU">EU</Country><Indication id="3144">Hyperammonemia</Indication><AwardedIndication>Treatment of ornithine translocase deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-13T00:00:00.000Z</MileStoneDate><Source id="1782604" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1066794">Lucane Pharma SA</OwnerCompany><Country id="EU">EU</Country><Indication id="3852">Carbamoyl phosphate synthase I deficiency</Indication><AwardedIndication>Treatment of carbamoyl-phosphate synthase-1 deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-16T00:00:00.000Z</MileStoneDate><Source id="1775672" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1066794">Lucane Pharma SA</OwnerCompany><Country id="EU">EU</Country><Indication id="1820">Ornithine transcarbamylase deficiency</Indication><AwardedIndication>Treatment of ornithine transcarbamylase deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-16T00:00:00.000Z</MileStoneDate><Source id="1775672" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1066794">Lucane Pharma SA</OwnerCompany><Country id="EU">EU</Country><Indication id="2284">Aminoaciduria</Indication><AwardedIndication>Treatment of hyperargininaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-16T00:00:00.000Z</MileStoneDate><Source id="1775672" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1066794">Lucane Pharma SA</OwnerCompany><Country id="EU">EU</Country><Indication id="2306">Citrullinuria</Indication><AwardedIndication>Treatment of citrullinaemia type 1</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-16T00:00:00.000Z</MileStoneDate><Source id="1775672" type="PR"></Source></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>c1ccc(cc1)C(=O)[O-].[Na+]</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>